Background Mutations in the gene encoding skeletal muscle glycogen phosphorylase (GP)

Background Mutations in the gene encoding skeletal muscle glycogen phosphorylase (GP) cause a metabolic disorder known as McArdle’s disease. cultures. GP immunoreactivity was mainly UK-427857 manufacturer due to brain and liver GP but muscle GP seemed to be responsible for the differences. Mouse monoclonal antibody to Hsp70. This intronless gene encodes a 70kDa heat shock protein which is a member of the heat shockprotein 70 family. In conjuction with other heat shock proteins, this protein stabilizes existingproteins against aggregation and mediates the folding of newly translated proteins in the cytosoland in organelles. It is also involved in the ubiquitin-proteasome pathway through interaction withthe AU-rich element RNA-binding protein 1. The gene is located in the major histocompatibilitycomplex class III region, in a cluster with two closely related genes which encode similarproteins Conclusions/Significance These results indicate that in both patients’ and controls’ cell cultures, unlike in skeletal muscle tissue, most of the protein and UK-427857 manufacturer GP activities result from the expression of brain GP and liver GP genes, although there is still some activity resulting from the expression of the muscle GP gene. More research is necessary to clarify the differential mechanisms of metabolic adaptations that McArdle cultures undergo (brain) (liver), and (skeletal muscle) [2]. In 1959, lack of muscle GP UK-427857 manufacturer was identified as the cause of a glycogenolytic defect confined to the skeletal muscles [3], [4]. The clinical features of this disorder, known as McArdle’s disease or glycogenolysis type V had first been described a few years earlier by Brian McArdle [5], and encompass exercise intolerance with reversible acute crises of premature fatigue, myalgia and contractures, sometimes accompanied by severe rhabdomyolysis and myoglobinuria; these episodes are triggered by static or isometric muscle contractions as well as by dynamic, strenuous exercises such as running [6]. Since the publication of the first pathogenic mutations in 1993 [7], [8], a growing allelic heterogeneity of the gene has been reported, with more than 100 mutations known to cause McArdle’s disease [9]. A stop-codon mutation, mutations in gene expression [10]. An RNA surveillance mechanism known as nonsense mediated mRNA decay (NMD), reduces the UK-427857 manufacturer mRNA levels of those transcripts that contain nonsense and frameshift mutations [11]. Our previous results support the notion that NMD is a common acting mechanism among McArdle patients, with 92% of them showing a reduced amount of mRNA levels [12]. GP activity in muscle biopsies and cultured muscle cells from McArdle patients has previously been studied. No detectable GP activity is observed in muscle biopsies from patients; however, cultured muscle cells derived from the same biopsies did present GP activity [13], [14], [15], [16]. It has also been described in regenerative fibers from McArdle patients [17]. This phenomenon was described as the mystery of the reappearing enzyme [17], [18], although it is not clear which specific GP isoform accounts for this activity, i.e. brain isoform [15], brain and liver isoform [16] vs. skeletal muscle isoform [13], [14]. In this study we have characterized the molecular alterations produced by a novel frameshift mutation (and was carried out in accordance with the Declaration of Helsinki for Human Research. Subjects We report two Caucasian brothers (index case P1, and P2), aged 43 and 51 years, from a small village in southern Spain, with family history of consanguinity but not of neuromuscular diseases. They both presented the four cardinal features of the disease [6]: (i) exercise intolerance since childhood; (ii) high serum levels of creatine kinase (CK) activity, even in basal conditions (672 Ul?1 and 344 Ul?1 at the moment of study, after 2 resting days, normal 170 Ul?1); (iii) previous episodes of hyper-CK-emia (7,000 and 10,000 Ul?1) plus myoglobinuria after intense exercise, indicating marked rhabdomyolysis; and (iv) the second wind phenomenon, depicted by a sudden, marked improvement tolerance to aerobic dynamic exercise (notably, brisk walking) after 8C10 minutes of exercise or after a short period of rest [19]. Their peak oxygen uptake (VO2peak) measured during incremental cycle-ergometer testing was very low (12.5 and 13.0 ml O2/kg/min), barely above the limits for independent living, which reflects a markedly decreased muscle oxidative capacity, another common feature of the disease [20]. Two sex- and age-matched healthy Spanish volunteers recruited for the study (C1, C2) served as controls (Table 1). Their VO2peak was 36 and 38 ml O2/kg/min. Table 1 Subjects’ information. genotype mRNA (%)sequencing in P1 and his brother (P2), who was also clinically affected (see above). gene was sequenced as follows: DNA was isolated from whole blood using a standard phenol-chloroform method (Nucleon BACC-2, GE healthcare Europe GMBH, Chalfont St. Giles, UK). We amplified the coding sequence of the entire gene by polymerase chain reaction (PCR) in 14 fragments, using the primers described by Kubisch et al [21]. For PCR analysis and sequencing, we adopted the methods explained elsewhere [22]. In order to perform a more exhaustive testing, we performed amplification of cDNA samples (observe below), having a.